about
Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialSynthetic self-adjuvanting glycopeptide cancer vaccinesMucins in neoplasms of pancreas, ampulla of Vater and biliary systemGlycoproteins and glycoproteomics in pancreatic cancerHEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucinEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsMUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway.Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.In vivo selection for spine-derived highly metastatic lung cancer cells is associated with increased migration, inflammation and decreased adhesion.Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy.Frontiers in Suicide Gene Therapy of Cancer.One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticlesMUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism.Suicide Gene Therapy for Cancer - Current Strategies.Advances in miRNA-Mediated Mucin Regulation.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.Differential gene expression of the key signalling pathway in para-carcinoma, carcinoma and relapse human pancreatic cancer.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.Benzyl isothiocyanate (BITC) induces apoptosis of GBM 8401 human brain glioblastoma multiforms cells via activation of caspase-8/Bid and the reactive oxygen species-dependent mitochondrial pathway.Tumour-associated antigens and their anti-cancer applications.Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours.Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines.What's new in treatment of pancreatic cancer: a patent review (2010-2017).Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.Electrochemical Characterization of Protein Adsorption onto YNGRT-Au and VLGXE-Au Surfaces.The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration.Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.Intraductal tubulopapillary neoplasm (ITPN) of the pancreas associated with an invasive component: a case report with review of the literature.Emerging trends in the immunotherapy of pancreatic cancer.Inhibition of MUC1 biosynthesis via threonyl-tRNA synthetase suppresses pancreatic cancer cell migration.Molecular Pathways: Mucins and Drug Delivery in Cancer.
P2860
Q26749451-6F8D4A52-BB0D-480F-A19E-311658011BFDQ26769884-07235546-799F-42F9-BBCA-65489EEFB9B0Q26777837-E780F654-AF7D-4BAE-93A6-B351AC621CABQ28070355-29FF6B32-FBC5-4E8C-95E1-35264E221BB4Q28071108-B2DD500D-5097-492B-85B6-E1F6F6FAD883Q30843463-53D01BE9-87A8-4AD0-8CFE-6156A43A8E66Q33588037-A3A81A7C-4472-46CD-8A1C-827F4C79394FQ33833475-BEF46EEC-4FFD-424F-925F-7A8F350292E5Q34381590-735F828A-2997-42DF-A84B-5DB465EFE0A3Q35749993-ED1B5532-60C9-422A-B4CF-F278510AA7A3Q36326344-7708E2D3-706A-46E6-A00D-02EAA35BB1BFQ36356108-23D52380-54F4-41E7-889C-D3000A8ABA07Q36437150-7FBF59AD-D1A2-43EF-8AB0-1B60A7F62C23Q36534930-8B3F8E6E-0A48-4407-9882-43557F5C48DAQ36957933-D810114A-FA48-4543-BC8F-FBD80D005D8EQ37033307-412D01D8-CD87-4CA6-8972-FB55AE134ADBQ37347017-0CFAABA0-515A-4B57-B399-7186C6E8462DQ37420793-CF70346E-89A8-4281-AC92-A90A7E03ABE1Q37559401-F6882D49-8A91-4270-B317-68FDF66C56DBQ38221692-62175730-C812-44D1-82AF-1362C9A497A3Q38302045-B4CEEECC-2FDB-4452-BA30-433BB98A051FQ38484647-CCAEA6AC-76D1-4D9E-8013-99B626FC60EAQ38591066-D249A4E9-547B-43E8-A6E7-8636B320CD9AQ38694458-63DD5BAD-CD5F-4C6D-BAE7-300E07E9B590Q38725552-CF0CA589-212D-4AC2-985D-CCA15CB73E61Q38809725-E9E4D2B5-4DD0-4863-927E-DA9BC2804570Q39149939-A9DC72B2-1B4E-4906-A233-5BC2B93FEF3AQ39406815-A92DA900-C7DC-49FF-AFD3-7B1AFD2B2D33Q39410445-18408502-5DD3-488F-9B60-9CF6018FF237Q41834456-BF7005AD-F765-47DA-A073-9AD67442C915Q42251507-4D841353-49E9-434E-8FE5-55791E3719B7Q42380545-ED4EA355-8013-4737-BECF-F7BEF5C81DBBQ44697408-C2B25199-6962-4E03-B186-3EF51FCB05C2Q47248817-BAE2AE54-EB42-47BA-AD69-40E37F8C5515Q50069871-AB58FE05-0540-4CC6-BE07-FFF98B407EFCQ50465411-EAE08EAC-6E92-4A89-8CCB-A7E978182DCC
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Mucin-based targeted pancreatic cancer therapy
@ast
Mucin-based targeted pancreatic cancer therapy
@en
Mucin-based targeted pancreatic cancer therapy
@nl
type
label
Mucin-based targeted pancreatic cancer therapy
@ast
Mucin-based targeted pancreatic cancer therapy
@en
Mucin-based targeted pancreatic cancer therapy
@nl
prefLabel
Mucin-based targeted pancreatic cancer therapy
@ast
Mucin-based targeted pancreatic cancer therapy
@en
Mucin-based targeted pancreatic cancer therapy
@nl
P2093
P2860
P3181
P1476
Mucin-based targeted pancreatic cancer therapy
@en
P2093
Maria P Torres
Subhankar Chakraborty
Surinder K Batra
P2860
P304
P3181
P356
10.2174/13816128112092472
P407
P577
2012-01-01T00:00:00Z